Congruence Therapeutics Announces Closing of $32M Financing to Advance First-in-Class Genetic Obesity Candidate Drug CGX-926 Through Phase 1b Proof of Concept Clinical Trial

CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity; CTA to be filed in 2H 2025

(Sep 04, 2025) by Congruence Therapeutics.

MONTREAL, Sept. 4, 2025 /PRNewswire/ — Congruence, a computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, including MC4R-deficient (MC4R-d) genetic obesity, GBA1-driven Parkinson’s disease and Alpha-1 antitrypsin (A1AT) deficiency, announced today the closing of a US $32 million financing round.

The round included participation from all existing investors including: Amplitude Ventures, FSTQ, Lumira, Investissement Quebec, BDC Capital’s Thrive Venture Fund, OrbiMed, Driehaus, Silver Arc, and Alexandria.